These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 26819103

  • 21. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
    Tolomeo A, Lopopolo G, Dimiccoli V, Perioli L, Modoni S, Scilimati A.
    Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
    [Abstract] [Full Text] [Related]

  • 22. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Feb; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 23. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 24. Heterogeneity of Multiple Pancreatic Neuroendocrine Tumors Identified by 68Ga-DOTANOC and 68Ga-Exendin-4 PET/CT in a Patient with Endogenous Hyperinsulinemic Hypoglycemia and Multiple Endocrine Neoplasia 1.
    Xu J, Xu X, Zhang M, Liu W, Chen J, Song S.
    Neuroendocrinology; 2024 Jun; 114(9):866-871. PubMed ID: 38471465
    [Abstract] [Full Text] [Related]

  • 25. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
    Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK.
    World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
    [Abstract] [Full Text] [Related]

  • 26. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
    Gaertner FC, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh RA, Sinnes JP, Rösch F, Essler M.
    Nucl Med Biol; 2019 Jun; 76-77():1-9. PubMed ID: 31520872
    [Abstract] [Full Text] [Related]

  • 27. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [Abstract] [Full Text] [Related]

  • 28. 68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.
    Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 Oct; 38(2):94-99. PubMed ID: 30630744
    [Abstract] [Full Text] [Related]

  • 29. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones-Jackson LB, Lakhani V, Baum RP, Berlin J, Smith GT, Graham M, Sandler MP, Delbeke D, Walker RC.
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [Abstract] [Full Text] [Related]

  • 30. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
    Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I.
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):532-40. PubMed ID: 16491425
    [Abstract] [Full Text] [Related]

  • 31. Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
    Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, Van Herpe F, Jaekers J, Cleeren F, Hofland J, Brouwers A, Koole M, Bormans G, Van Cutsem E, Geboes K, Laenen A, Verslype C, Stroobants S, Deroose CM.
    J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825
    [Abstract] [Full Text] [Related]

  • 32. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015 Aug; 143(1-2):108-15. PubMed ID: 25845263
    [Abstract] [Full Text] [Related]

  • 33. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
    Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
    [Abstract] [Full Text] [Related]

  • 34. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.
    J Clin Oncol; 2016 Feb 20; 34(6):588-96. PubMed ID: 26712231
    [Abstract] [Full Text] [Related]

  • 35. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L, Ravelli I, Bignotto A, Cecchin D, Zucchetta P.
    Clin Imaging; 2020 Nov 20; 67():113-116. PubMed ID: 32559681
    [Abstract] [Full Text] [Related]

  • 36. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT.
    Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Apr 20; 40(4):514-23. PubMed ID: 23291643
    [Abstract] [Full Text] [Related]

  • 37. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
    Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ.
    J Nucl Med; 2009 Aug 20; 50(8):1214-21. PubMed ID: 19617343
    [Abstract] [Full Text] [Related]

  • 38. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC.
    Invest Radiol; 2013 May 20; 48(5):273-9. PubMed ID: 23493121
    [Abstract] [Full Text] [Related]

  • 39. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar 20; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 40. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B.
    Nucl Med Commun; 2013 Aug 20; 34(8):727-32. PubMed ID: 23728519
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 38.